CDC and FDA release Beyfortus for infant RSV shortage

Physician's Weekly November 20, 2023, 07:00 AM UTC
Significance6.5
Scale8.0
Magnitude7.5
Potential8.5
Novelty9.0
Actionability7.0
Immediacy9.5
Credibility8.0

The U.S. CDC and FDA released over 77,000 doses of Beyfortus, a long-acting monoclonal antibody for infants too young for RSV vaccination, to address a nationwide shortage. The doses will be distributed immediately through federal programs and commercial channels. The CDC is working to make the shots more accessible for doctors. Beyfortus is prioritized for high-risk infants, while an alternative, Synagis, is recommended for older children. This is the first RSV season Beyfortus is available.

Source

Hi! My name is Vadim.

I built this site because I wanted to have a way to read only important news.

It uses ChatGPT to analyze articles on seven factors and calculate a final significance score from 0 to 10.

See today's rankings on the main page.